Industry Reports Services Press Release
  •   Blogs
  • Contact us About us

    North America Autoimmune Disease Diagnostics Market Forecast 2028 By Test Type (Antinuclear Antibody Tests, Autoantibody Tests, C-reactive Protein (CRP), Complete Blood Count (CBC), Urinalysis), By Product (Systemic Autoimmune Disease {Rheumatoid arthritis, Ankylosing spondylitis, Systemic Lupus Erythematosus}, Localized Autoimmune Disease), Research Report, Country Outlook (U.S., Canada), COVID-19 Impact Statistics, Price Trends, Historic Data, Growth Prospects, Competitive Industry Share
    Published Date: August 2022   |   Report ID: GR1275   |   Delivery: PDF  Request Free Sample

    North America Autoimmune Disease Diagnostics Market size exceeded USD 380 million in 2021 and is anticipated to register a CAGR of 6% between 2022 and 2028. A steady rise in the incidence of rare autoimmune conditions across Canada and the U.S. has triggered the market growth.

    North America Autoimmune Disease Diagnostics Market

    Get more details on this report - Request Free Sample PDF

    Over the last few years, the number of patients suffering from rheumatoid arthritis, multiple sclerosis, type 1 diabetes mellitus, and Graves’ disease has been increasing at a concerning rate. As most of these conditions do not have a cure yet, organizations such as the National Institutes of Health (NIH) and the Autoimmune Association have been working to improve awareness, education, diagnosis, and treatment at every step of patient’s journey. Various programs and policies are aiming for early diagnosis as it can determine a patient’s survival rate. Emphasis on adequate access to autoimmune disease diagnosis is rising, as patients suffering from these conditions experience debilitating symptoms, organ function loss, reducing productivity, and a lifetime of illness.

    As these conditions often result in a number of chronic illnesses, healthcare providers as well as government authorities have been dealing with substantial financial burden. With a view to address these concerns, several public and private initiatives will focus in providing early and accurate diagnosis to these patients. There are awareness campaigns conducted by local bodies such as the American Autoimmune related Diseases Association (AARDA). With this, more individuals are growing conscious about autoimmune conditions, their diagnosis, and the available treatment options.

    Impact of COVID-19 on North America Autoimmune Disease Diagnostics Market:

    During 2020, the large percentage of patients with autoimmune diseases suffered from COVID-19. In fact, some studies conducted over the last couple of years reveals that autoantibodies that were present in a patient’s body even before the SARS-CoV-2 infection was detected, accounted for nearly 20% of high risk COVID-19 cases. Growing evidence suggests a strong link between autoimmune disease and the novel coronavirus, wherein the infection could be a factor triggering the production of autoantibodies amongst other people. Due to these unsettling questions, investments in the development of effective autoimmune disease screening tests have been increasing.

    North America Market, By Test Type

    The antinuclear antibody (ANA) tests segment will surpass USD 270 million revenue by 2028. More patients have been taking these tests for determining the type of autoimmune condition affecting them. Since these tests provide crucial information such as the amount of ANA in patients’ blood samples, they can reveal an underlying abnormality. Growing incidence of lupus and similar disorders will continue to fuel product uptake. Due to high sensitivity, the antinuclear antibody immunofluorescence assay is often a first-line diagnostic test preferred by physicians for people with suspected autoimmune disorders.

    North America Market, By Product

    The ankylosing spondylitis (AS) segment is expected to record a steady growth during the forecast period. Since ankylosing spondylitis occurs more frequently in the younger population segment, it is more difficult to diagnose. According to the Centers for Disease Control and Prevention, more than 1.7 million individuals in the U.S. have ankylosing spondylitis, whereas over 3.2 million suffer from some form of axial spondyloarthritis. The need for timely diagnosis for the disorder will generate considerable opportunities for diagnostic solution providers.

    North America Market, By Country

    U.S. autoimmune disease diagnostics market size is slated to expand at a substantial rate through 2028, driven by the introduction of novel testing technologies across diagnostic centers. More investors have been displaying interest in upgrading laboratory equipment for delivering faster and more comprehensive test results. Presence of well-trained rheumatologists in the nation has enabled smoother diagnosis of conditions affecting ligaments, muscles, tendons, bones, connective tissues, and joints.

    Competitive Industry Landscape

    Some of the leading players involved in the North America market include Inova Diagnostics, Inc., Hemagen Diagnostics, Abbott Laboratories, Crescendo Bioscience, Inc., Beckman Coulter, Inc., Quest Diagnostics, F. Hoffmann-La Roche Ltd, SQI diagnostics, and Siemens Healthineers.

    These companies have been focusing on introducing breakthrough products to address customer pain points. Recently, in June 2022, Thermo Fisher Scientific added the expanded capabilities of its novel Phadia 2500+ product line for scalable and high-performance autoimmune testing, that can perform and deliver over 10,000 test results on a weekly basis.


    Frequently Asked Question(FAQ) :

    What is the value of North America autoimmune disease diagnostics market?
    The market for autoimmune disease diagnostics in North America was valued at over USD 380 million during 2021 and could register over 6% CAGR through 2022-2028.
    Why is the demand for the antinuclear antibody tests increasing in the North America autoimmune disease diagnostics sector?
    The antinuclear antibody (ANA) tests is estimated to exceed USD 270 million by 2028 with surging incidence of lupus and similar disorders.
    What are the factors boosting US autoimmune disease diagnostics industry?
    The market size for autoimmune disease diagnostics in US will record continuous developments with increased investments in upgrading laboratory equipment and the adoption of novel testing solutions across diagnostic centers.
    Who provides autoimmune disease diagnostics solutions in North America?
    A few of the leading companies in the market include Beckman Coulter, Inc., F. Hoffmann-La Roche Ltd, Inova Diagnostics, Inc., Hemagen Diagnostics, Siemens Healthineers, Abbott Laboratories, Crescendo Bioscience, Inc., Quest Diagnostics, SQI diagnostics, among others.

    Get this research report on North America Autoimmune Disease Diagnostics Market customized according to your business requirements.

    report-purchase - logo Buy Now

    Why Choose us?

    • on-time delivery On-Time Delivery

      We commit to on-time delivery of reports to keep you ahead.

    • assured quality Assured Quility

      With a wide network of industry experts and trained in-house analysts, we assure best service quality.

    • Custom Research Service

      We offer research services to meet specific client requirements and provide them with actionable insights on target markets.

    • payment security Payment Security

      Our safe payment gateway gives you full control of your personal data, at all times.

    Connect with our sales team


     [email protected]